ZA926063B - Escherichia coli-polysaccharide-protein conjugate vaccine. - Google Patents

Escherichia coli-polysaccharide-protein conjugate vaccine.

Info

Publication number
ZA926063B
ZA926063B ZA926063A ZA926063A ZA926063B ZA 926063 B ZA926063 B ZA 926063B ZA 926063 A ZA926063 A ZA 926063A ZA 926063 A ZA926063 A ZA 926063A ZA 926063 B ZA926063 B ZA 926063B
Authority
ZA
South Africa
Prior art keywords
polysaccharide
present
coli
vaccines
escherichia coli
Prior art date
Application number
ZA926063A
Other languages
English (en)
Inventor
Stanley J Cryz
Emil P Furer
Original Assignee
Schweiz Serum & Impfinst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst filed Critical Schweiz Serum & Impfinst
Publication of ZA926063B publication Critical patent/ZA926063B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA926063A 1991-08-12 1992-08-12 Escherichia coli-polysaccharide-protein conjugate vaccine. ZA926063B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/743,787 US5370872A (en) 1991-08-12 1991-08-12 Escherichia coliO-polysaccharide-protein conjugate vaccine

Publications (1)

Publication Number Publication Date
ZA926063B true ZA926063B (en) 1993-05-19

Family

ID=24990179

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA926063A ZA926063B (en) 1991-08-12 1992-08-12 Escherichia coli-polysaccharide-protein conjugate vaccine.

Country Status (12)

Country Link
US (1) US5370872A (de)
EP (1) EP0598818B1 (de)
JP (1) JP2763960B2 (de)
AT (1) ATE198989T1 (de)
AU (1) AU669854B2 (de)
CA (1) CA2115564C (de)
DE (1) DE69231673T2 (de)
DK (1) DK0598818T3 (de)
ES (1) ES2154263T3 (de)
GR (1) GR3035662T3 (de)
WO (1) WO1993003765A1 (de)
ZA (1) ZA926063B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
EP0716613B1 (de) * 1993-07-27 2003-07-09 Csl Limited Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
US6872398B2 (en) * 1995-12-22 2005-03-29 The United States Of America As Represented By The Secretary Of The Army Conjugate vaccine against gram-negative bacterial infections
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
WO1998026799A1 (en) * 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6749831B1 (en) * 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
WO2000070060A1 (en) * 1999-05-18 2000-11-23 University Of Iowa Research Foundation Production of complex carbohydrates
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
AU2001253568A1 (en) * 2000-04-18 2001-10-30 Dan C. Deborde Lipopolysaccharide-conjugate vaccine for sepsis treatment
EP1438387A4 (de) * 2001-09-14 2004-10-13 Momenta Pharmaceuticals Inc Verfahren zur herstellung von glycomolekülen mit verstärkten aktivitäten und verwendungen davon
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
CA2703519C (en) 2007-11-09 2017-04-18 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
WO2012125553A2 (en) 2011-03-12 2012-09-20 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing n-glycans in glycoprotein products
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
WO2014018747A2 (en) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
EP3058084A4 (de) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylierte glycoproteine
KR102301188B1 (ko) 2014-02-06 2021-09-13 엑스4 파마슈티컬스 (오스트리아) 게엠베하 이. 콜라이 특이성 항체 서열
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
US11260119B2 (en) * 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CN116888140A (zh) 2021-01-12 2023-10-13 杨森制药公司 FimH突变体、其组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US5034516A (en) * 1987-08-04 1991-07-23 University Of Ottawa Synthetic antigens of sialic acid and derivatives thereof
AU5675790A (en) * 1989-05-09 1990-11-29 Cetus Corporation Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria

Also Published As

Publication number Publication date
DE69231673D1 (de) 2001-03-08
US5370872A (en) 1994-12-06
DK0598818T3 (da) 2001-03-19
DE69231673T2 (de) 2001-06-07
WO1993003765A1 (en) 1993-03-04
CA2115564C (en) 2002-01-22
JPH06510530A (ja) 1994-11-24
ATE198989T1 (de) 2001-02-15
JP2763960B2 (ja) 1998-06-11
AU2464192A (en) 1993-03-16
EP0598818A1 (de) 1994-06-01
AU669854B2 (en) 1996-06-27
ES2154263T3 (es) 2001-04-01
EP0598818A4 (de) 1995-04-05
CA2115564A1 (en) 1993-03-04
EP0598818B1 (de) 2001-01-31
GR3035662T3 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
GR3035662T3 (en) Escherichia coli o-polysaccharide-protein conjugate vaccine.
EP2026841B1 (de) Konjugationsverfahren für pnag und ein trägerprotein
FI110164B (fi) Menetelmä oligosakkaridin valmistamiseksi depolymeroimalla antigeeninen polysakkaridi
AU748973B2 (en) Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
KR100431236B1 (ko) 2,5-안히드로-d-만노오스터미널구조를갖는항원성b족연쇄구균타입ⅱ및타입ⅲ다당류및그의복합백신
CN105267974A (zh) 用于缀合疫苗的经过修饰的多糖
EA020459B1 (ru) Иммуногенная композиция
JP7439174B2 (ja) 免疫原性コンジュゲート及びその使用
EP0977588B1 (de) Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
JP2002513028A (ja) ポリサッカリド抗原結合体
AU7580787A (en) Lipopolysaccharides of reduced toxicity and the production thereof
US12053515B2 (en) Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
KR101044437B1 (ko) ５ 혈청형 폐렴연쇄구균 피막 폴리사카라이드의 환원적아민화에 의해 수득된 접합체
KR102428253B1 (ko) 신규한 다당류-단백질 접합체 및 이의 제조방법
KR950703361A (ko) 그룹 b 스트렙토코쿠스 ⅱ형 및 v형 다당류-단백질 결합 백신
CA2406229A1 (en) Anti-sepsis conjugate vaccine
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
KR970706845A (ko) 식물 또는 과실의 폴리사카라이드로부터 합성된 장티푸스 백신 및 그 제법(synthesis of typhoid fever vaccine from a plant or fruit polysaccharide)
Cryz et al. Escherichia coliopolysaccharide-protein conjugate vaccine
ES2135355A1 (es) Vacuna anti-vibrio anguillarum (gava-3) para la prevencion de la enfermedad vibriosis del rodaballo y peces salmonidos, y procedimiento de obtencion.
Arndt et al. Strategies for type-specific glycoconjugate vaccines of Streptococcus pneumoniae
CN118203657A (zh) 一种多糖结合疫苗及其制备方法和用途
MXPA98007617A (es) Conjugados de polisacaridos peptidos